Avitar to Participate in ASSE Technical Meeting on Workplace Substance Abuse Testing

CANTON, Mass., Feb. 9  /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC:AVRN) (BULLETIN BOARD: AVRN) , developer of the world's first on-site, oral fluid-based test for drugs-of-abuse, will present at the "Workplace Substance Abuse Testing" technical meeting organized by the Greater Boston Chapter of the American Society of Safety Engineers (ASSE).  Steve Turko, National Accounts Director for Construction of Avitar was invited to speak at the event beginning at 5:30 pm on February 15, 2006 at Desmond O'Malley's Irish Pub & Restaurant in Framingham, MA.

During his presentation, Turko will discuss the advantages of oral fluid- based on-site drug testing, one of the most cost-effective and reliable methods to reduce employee drug abuse.  Additionally, Turko will highlight strategies for implementing successful drug testing programs, specifically: the advantages of random drug testing in reducing accidents, creating a better work environment for all employees and improving a corporation's bottom line.

Other panelists at the meeting will examine various alternative methods for substance abuse testing, which will be followed by a question and answer session for attendees.

  WHO:    Steve Turko, National Accounts Director, Construction, Avitar Inc.
  WHAT:   "Workplace Substance Abuse Testing 101"
  WHEN:   Wednesday, February 15, 2006 from 5:30 to 8.30 p.m.
  WHERE:  Desmond O'Malley's Irish Pub & Restaurant
          Route 9 East
          Framingham, MA

  About Avitar


Avitar, Inc. develops, manufactures and markets innovative and proprietary products.  Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry.  Avitar manufactures ORALscreen(R), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating wounds.  Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy.  For more information, see Avitar's website at http://www.avitarinc.com/.

  Company Contact:                     PR Contact:
  Peter Cholakis                       Maura Landry
  Avitar Inc.                          SHIFT Communications
  781-821-2440 x117                    617-681-1229
                

First Call Analyst: 

FCMN Contact: 

DATASOURCE: Avitar, Inc.



CONTACT:  Peter Cholakis of Avitar Inc., [phone] ext. 117,

; or Maura Landry of SHIFT Communications,

[phone], 



Web site:  http://www.avitarinc.com/

Copyright